Disease Info Card

Diffuse Large B-cell Lymphoma

Information about Diffuse Large B-cell Lymphoma: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Diffuse Large B-cell Lymphoma

Most recent studies have shown that Diffuse Large B-cell Lymphoma shares some biological mechanisms with b-cell-lymphomas, burkitt-lymphoma, carcinoma, chronic-lymphocytic-leukemia, histiocytic-sarcoma, hodgkin-disease, ki-1--anaplastic-large-cell-lymphoma, leukemia, lymphoid-leukemia, lymphoma, lymphoma-follicular, lymphoma-non-hodgkin, malignant-neoplasms, malignant-paraganglionic-neoplasm, neoplasm-metastasis, neoplasms, sarcoma, skin-neoplasms, stomach-neoplasms, t-cell-lymphoma.

Among the many pathways, these few ones have gauged particular interests from scientists studying Diffuse Large B-cell Lymphoma, and have been seen in publications frequently: Angiogenesis, Cell Adhesion, Cell Cycle, Cell Cycle Arrest, Cell Death, Cell Differentiation, Cell Growth, Cell Proliferation, Drug Resistance, Immune Response, Induction Of Apoptosis, Interphase, Localization, Methylation, Oncogenesis, Pathogenesis, Phagocytosis, Reverse Transcription, S Phase, Secretion

Quite a number of genes have been found to play important roles in Diffuse Large B-cell Lymphoma, such as ALK, BCL2, BCL6, CD5, CTLA4, DDIT3, HLA-DQA1, KRT20, MID1, MME, MS4A1, MYC, NOD2, NPM1, PTPRC, TNF, TNFRSF8, TP53. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.